摘要
“胆固醇学说”奠定了动脉粥样硬化性心血管疾病的治疗基础,但研究证明“炎症反应学说”是有关动脉粥样硬化(AS)的另一研究热点,也是AS干预的潜在靶点。前蛋白转化酶枯草溶菌素9(PCSK9)具有脂质调节和炎症反应介导的多效性,可通过脂质驱动炎症反应,同时也是一种独立的炎症介质参与AS的发生,PCSK9的炎症反应效应可能是中医药治疗AS的重要靶点之一。中药及其提取物(槲皮素、盐酸小檗碱、绞股蓝苷、姜黄素、10-脱氢姜二酮和甘蔗原素、银杏内酯B、柚皮苷和橙皮苷等)、中药复方(首参颗粒、芪蛭通脉颗粒等)对PCSK9有抑制作用,是PCSK9药物研究和发掘的一个重要方向。
The cholesterol hypothesis has laid a foundation for the treatment of atherosclerotic cardiovascular disease.The theory of inflammation is garnering increasing attention in the research on atherosclerosis,and inflammation is a potential target in the intervention in this disease.Proprotein convertase subtilisin/kexin type 9(PCSK9) has multiple effects of regulating lipid levels and mediating inflammation.PCSK9 can drive inflammation via lipids and acts as an independent inflammatory mediator in the occurrence of atherosclerosis.The inflammatory effect of PCSK9 may be one of the targets for the treatment of atherosclerosis with traditional Chinese medicine.Chinese medicines and their active components(quercetin,berberine hydrochloride,gypenoside,curcumin,10-dehydrogingerdione,policosanol,ginkgolide B,naringin,and hesperidin) as well as Chinese medicine prescriptions(such as Shoushen Granules and Qizhi Tongmai Granules) demonstrate inhibitory effects on PCSK9,which is an important direction for the research and discovery of PCSK9-based drugs.
作者
姜益宏
曾海飞
徐先增
李健
周伟民
李莲
何亚州
许志亮
JIANG Yihong;ZENG Haifei;XU Xianzeng;LI Jian;ZHOU Weimin;LI Lian;HE Yazhou;XU Zhiliang(Guangxi University of Chinese Medicine,Nanning 530200,China;Guangxi International Zhuang Medicine Hospital,Nanning 530201,China;Guangzhou University of Chinese Medicine,Guangzhou 510006,China)
出处
《世界中医药》
CAS
北大核心
2024年第12期1846-1851,共6页
World Chinese Medicine
基金
广西自然科学基金面上项目(2018JJA140751)
广西高校中青年教师科研基础能力提升项目(2022KY0285)。
